Loading
Alcon Inc. Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest was filed 07 May 2026.
Alcon Inc.: what insiders have been doing
Alcon Inc., classified in the Healthcare & Pharma sector, is a listed company based in Geneva, Switzerland, founded in 1945. Its insiders report their share dealings to SIX SER. In the past year (18 October 2025 to 18 October 2026), 10 filings came from 3 insiders.
Open-market activity splits into 8 purchases totalling €1.3M and 2 sales totalling €1.3M; 2 insiders sit on the buying side and 1 insider on the selling side. Purchases outweigh sales by €32k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a sale of €1.1M, published on 26 February 2026. Among those who bought: 2 senior executives.
In the case of 5 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last purchase on record was published on 7 May 2026, which is 163 days ago. Publication is fast: at least half of the trades appear on SIX SER on the same day. That lag is the time during which only the insider knows about the trade.
For context, the typical company on the same exchange (median of 178 companies) published 9 filings over the same period, against 10 filings here. Our records for Alcon Inc. go back to 2023, with 22 purchases and 17 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SIX SER and describes the past, not future prices; it is not investment advice.
Insider Decl.
39
Thresholds
n/a
Buy Volume
€4M
22 ops. · all time
Sell Volume
€22M
17 ops. · all time
Who traded when
BuySaleAnonymous (Non-executive member of the board of directors)13 buys
Anonymous (Executive member of the board of directors / member of senior management)5 sales
Anonymous (a non-executive member of the board of directors)4 buys
Since the insiders bought
- Anonymous (a non-executive member of the board of directors)+17.6%Entry CHF 48.75 · Close at T+90 CHF 57.34
- Anonymous (Non-executive member of the board of directors)+12.1%Entry CHF 49.17 · Close 15 Oct 2026 CHF 55.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alcon Inc. Buy (bullish), based on 17 analysts. Average price target: CHF 73.97.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,615 of 24,148 companies
62.9
score / 100
Value59
Quality67
FCF yld5.7%
Earn yld3.5%
EV/EBITDA10.7x
ROE2.9%
Gross mgn55%
Net mgn9.4%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 58.56
Analyst consensus
17 analystsBuy
CHF 47.95Target CHF 73.97(+26%)CHF 85.03
Income statement
RevenueCHF 10.4B
Gross profitCHF 5.7B55% margin
EBITDACHF 2.7B26% margin
Net incomeCHF 980M5.9% margin
Valuation
PER (trailing)55.8x
PER (forward)13.4x
P/Book1.6x
Beta0.69
Balance sheet & cash
Market capCHF 28.3B
Total debtCHF 509M
Free Cash FlowCHF 1.6B
Debt / Equity25%
Profitability & ownership
ROE2.9%
ROA2.8%
% insiders0.2%
% institutions66.1%
Last declaration on 7 May 2026
Declarations39 total
3,000 shares@ CHF 51.140.0007% mcap25.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5700083
Canonical exit: 5 Aug 2026 (T+90)
3,000 shares@ CHF 51.1350.0007% mcap5.4% of flowISIN CH0432492467SIX:T1Q5700083
Canonical exit: 5 Aug 2026 (T+90)
1 shares@ CHF 85,000.000.0004% mcap14.1% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00049
Canonical exit: 29 Jul 2026 (T+90)
1 shares@ CHF 172,500.000.0008% mcap28.7% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00023
Canonical exit: 29 Jul 2026 (T+90)
1 shares@ CHF 190,000.000.0008% mcap31.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4U00031
Canonical exit: 29 Jul 2026 (T+90)
1 shares@ CHF 85,000.000.0004% mcap3.0% of flowISIN CH0432492467SIX:T1Q4U00049
Canonical exit: 29 Jul 2026 (T+90)
1 shares@ CHF 190,000.000.0008% mcap6.7% of flowISIN CH0432492467SIX:T1Q4U00031
Canonical exit: 29 Jul 2026 (T+90)
1 shares@ CHF 172,500.000.0008% mcap6.1% of flowISIN CH0432492467SIX:T1Q4U00023
Canonical exit: 29 Jul 2026 (T+90)
▼
Anonymous (Executive member of the board of directors / member of senior management)
2,412 shares@ CHF 67.2420.8% of flowISIN CH0432492467SIX:T1Q2Q00066
15,000 shares@ CHF 66.9735.0% of flowISIN CH0432492467SIX:T1Q2Q00074
10,000 shares@ CHF 63.658421.9% of flowISIN CH0432492467SIX:T1P8S00045
Canonical exit: 26 Nov 2025 (T+90)
2,000 shares@ CHF 64.804.4% of flowISIN CH0432492467SIX:T1P8L00024
Canonical exit: 19 Nov 2025 (T+90)
1,560 shares@ CHF 63.72133.4% of flowISIN CH0432492467SIX:T1P8L000G5
Canonical exit: 19 Nov 2025 (T+90)
1,250 shares@ CHF 63.4182.7% of flowISIN CH0432492467SIX:T1P8L00032
Canonical exit: 19 Nov 2025 (T+90)
1,000 shares@ CHF 62.962.2% of flowISIN CH0432492467SIX:T1P8L00099
Canonical exit: 19 Nov 2025 (T+90)
3,000 shares@ CHF 73.007.5% of flowISIN CH0432492467SIX:T1P5F00097
Canonical exit: 13 Aug 2025 (T+90)
1 shares@ CHF 167,500.005.8% of flowISIN CH0432492467SIX:T1P5600053
Canonical exit: 4 Aug 2025 (T+90)
1 shares@ CHF 150,000.005.2% of flowISIN CH0432492467SIX:T1P5600038
Canonical exit: 4 Aug 2025 (T+90)
1 shares@ CHF 147,500.005.1% of flowISIN CH0432492467SIX:T1P5600046
Canonical exit: 4 Aug 2025 (T+90)
12,600 shares@ CHF 83.97155.1% of flowISIN CH0432492467SIX:T1P33000F8
20,000 shares@ CHF 82.96228.1% of flowISIN CH0432492467SIX:T1P2S00063
▼
Anonymous (Executive member of the board of directors / member of senior management)
9,000 shares@ CHF 82.43823.6% of flowISIN CH0432492467SIX:T1P2R00057
▼
Anonymous (Executive member of the board of directors / member of senior management)
10,000 shares@ CHF 85.2644.1% of flowISIN CH0432492467SIX:T1O9C00030
112,182 shares@ CHF 85.535946.3% of flowISIN CH0432492467SIX:T1O9C00063
▼
Anonymous (Executive member of the board of directors / member of senior management)
4,622 shares@ CHF 81.87671.8% of flowISIN CH0432492467SIX:T1O9900049
25 of 39 declarations
About Alcon Inc.
Alcon Inc. is a global eye-care company listed on the SIX Swiss Exchange (SMI/SPI) and domiciled in Switzerland, with its global headquarters in Geneva. The company is one of the world’s leading ophthalmology names, with a strong position in both surgical eye care and vision care. Its roots go back to 1945, when it was founded in Fort Worth, Texas, by two pharmacists. After decades as part of Novartis, Alcon was separated into an independent public company in 2019.
Alcon’s business model is built around two core segments: Surgical and Vision Care. The Surgical division includes equipment, consumables and systems used in cataract, refractive and vitreoretinal procedures, as well as phacoemulsification platforms, lasers, implants and related surgical instruments. The Vision Care segment covers contact lenses, lens care products, artificial tears and other eye-health and comfort products. This dual structure gives Alcon exposure to both high-innovation medical devices and recurring consumer-oriented eye-care demand.
Read moreShow less
From a competitive standpoint, Alcon holds a solid position in a highly specialized global market that features high barriers to entry, meaningful regulatory hurdles and a constant need for clinical innovation. The company benefits from a large installed base of surgical equipment, a recognized brand and a broad portfolio spanning the eye-care continuum. It is commonly regarded as the global leader in eye-care devices, with commercial reach across North America, Europe, Asia-Pacific and emerging markets, supported by R&D, manufacturing and distribution capabilities in multiple geographies.
Key products and solutions include cataract surgery platforms, surgical visualization and aspiration systems, Air Optix and DAILIES contact lenses, as well as products addressing dry eye and everyday visual comfort. Alcon regularly highlights new product launches and technological advances, which support its defensive profile and its ability to refresh the portfolio over time.
Recent developments have centered on innovation and strategic M&A. In 2025, Alcon announced new product launches and disclosed acquisition activity, including LENSAR and an amended agreement to acquire STAAR Surgical, strengthening its position in refractive surgery and laser-enabled vision correction solutions. For investors, Alcon offers a quality healthcare exposure, global diversification and a long-term growth profile supported by demographic aging and structural demand for eye care.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
